EXHIBIT 1
JOINT FILING AGREEMENT
The undersigned agree that the statement on Schedule 13G with respect to the Ordinary Shares, nominal value £0.05 per share (the “Shares”), of Silence Therapeutics plc. is, and any amendments thereto signed by each of the undersigned shall be, filed on behalf of each of them pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.
Dated: September 1, 2023
INVUS PUBLIC EQUITIES, L.P. | ||
By: | INVUS PUBLIC EQUITIES ADVISORS, LLC, its general partner | |
By: | /s/ Raymond Debbane | |
Name: | Raymond Debbane | |
Title: | President | |
INVUS PUBLIC EQUITIES ADVISORS, LLC | ||
By: | /s/ Raymond Debbane | |
Name: | Raymond Debbane | |
Title: | President | |
ARTAL INTERNATIONAL S.C.A. | ||
By: | ARTAL INTERNATIONAL MANAGEMENT S.A., its managing partner | |
By: | /s/ Anne Goffard | |
Name: | Anne Goffard | |
Title: | Managing Director | |
ARTAL INTERNATIONAL MANAGEMENT S.A. | ||
By: | /s/ Anne Goffard | |
Name: | Anne Goffard | |
Title: | Managing Director | |
ARTAL GROUP S.A. | ||
By: | /s/ Anne Goffard | |
Name: | Anne Goffard | |
Title: | Authorized Person |
WESTEND S.A. | ||
By: | /s/ Anne Goffard | |
Name: | Anne Goffard | |
Title: | Managing Director | |
STICHTING ADMINISTRATIEKANTOOR WESTEND | ||
By: | /s/ Amaury Wittouck | |
Name: | Amaury Wittouck | |
Title: | Sole Member of the Board | |
MR. AMAURY WITTOUCK | ||
By: | /s/ Amaury Wittouck |